Clinical Trial Detail

NCT ID NCT01848756
Title Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Esanex Inc.
Indications

urinary system cancer

Her2-receptor positive breast cancer

esophageal cancer

non-small cell lung carcinoma

Therapies

SNX-5422

Age Groups: adult

Additional content available in CKB BOOST